

References

X-5020

1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). PET myocardial perfusion imaging for the detection of coronary artery disease clinical assessment. TEC Assessments. 1995;Volume 10:Tab 21.
2. Diamond GA, Forrester JS, Hirsch M, et al. Application of conditional probability analysis to the clinical diagnosis of coronary artery disease. *J Clin Invest*. May 1980;65(5):1210-1221. PMID 6767741.
3. Angelidis G, Giamouzis G, Karagiannis G, et al. SPECT and PET in ischemic heart failure. *Heart Fail Rev*. Mar 2017;22(2):243-261. PMID 28150111.
4. Food and Drug Administration (FDA). PET drugs - current good manufacturing practice (CGMP). 2009; <https://www.fda.gov/downloads/drugs/guidances/ucm070306.pdf>. Accessed August 23, 2018.
5. Food and Drug Administration (FDA). PET drugs - current good manufacturing practice (CGMP) (small entity compliance guide). 2011; <https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm266640.pdf>. Accessed August 23, 2018.
6. Food and Drug Administration (FDA). Guidance: Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs. 2012; <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291573.pdf>. Accessed August 23, 2018.
7. Beanlands RS, Chow BJ, Dick A, et al. CCS/CAR/CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease-- executive summary. *Can J Cardiol*. Feb 2007;23(2):107-119. PMID 17311116.
8. Knuuti J, Ballo H, Juarez-Orozco LE, et al. The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: a meta-analysis focused on post-test disease probability. *Eur Heart J*. May 29 2018. PMID 29850808.
9. Dai N, Zhang X, Zhang Y, et al. Enhanced diagnostic utility achieved by myocardial blood analysis: A meta-analysis of noninvasive cardiac imaging in the detection of functional coronary artery disease. *Int J Cardiol*. Oct 15 2016;221:665-673. PMID 27423088.
10. Jaarsma C, Leiner T, Bekkers SC, et al. Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and positron emission tomography imaging for the detection of obstructive coronary artery disease: a meta-analysis. *J Am Coll Cardiol*. May 8 2012;59(19):1719-1728. PMID 22554604.
11. Parker MW, Iskandar A, Limone B, et al. Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease: a bivariate meta-analysis. *Circ Cardiovasc Imaging*. Nov 2012;5(6):700-707. PMID 23051888.

12. Takx RA, Blomberg BA, El Aidi H, et al. Diagnostic accuracy of stress myocardial perfusion imaging compared to invasive coronary angiography with fractional flow reserve meta-analysis. *Circ Cardiovasc Imaging*. Jan 2015;8(1). PMID 25596143.
13. Chen A, Wang H, Fan B, et al. Prognostic value of normal positron emission tomography myocardial perfusion imaging in patients with known or suspected coronary artery disease: a meta-analysis. *Br J Radiol*. Jun 2017;90(1074):20160702. PMID 28306335.
14. Smulders MW, Jaarsma C, Nelemans PJ, et al. Comparison of the prognostic value of negative non-invasive cardiac investigations in patients with suspected or known coronary artery disease-a meta-analysis. *Eur Heart J Cardiovasc Imaging*. Sep 1 2017;18(9):980-987. PMID 28329376.
15. Knesaurek K, Machac J. Comparison of 18F SPECT with PET in myocardial imaging: a realistic thorax-cardiac phantom study. *BMC Nucl Med*. Oct 31 2006;6:5. PMID 17076890.
16. Slart RH, Bax JJ, de Boer J, et al. Comparison of 99mTc-sestamibi/18FDG DISA SPECT with PET for the detection of viability in patients with coronary artery disease and left ventricular dysfunction. *Eur J Nucl Med Mol Imaging*. Aug 2005;32(8):972-979. PMID 15824927.
17. Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging- assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). *J Am Coll Cardiol*. Nov 13 2007;50(20):2002-2012. PMID 17996568.
18. Mc Ardle B, Shukla T, Nichol G, et al. Long-term follow-up of outcomes with F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction secondary to coronary disease. *Circ Cardiovasc Imaging*. Sep 2016;9(9). PMID 27609816.
19. Siebelink HM, Blanksma PK, Crijns HJ, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. *J Am Coll Cardiol*. Jan 2001;37(1):81-88. PMID 11153777.
20. Srivatsava MK, Indirani M, Sathyamurthy I, et al. Role of PET-CT in the assessment of myocardial viability in patients with left ventricular dysfunction. *Indian Heart J*. Sep - Oct 2016;68(5):693-699. PMID 27773409.
21. Herzog BA, Husmann L, Valenta I, et al. Long-term prognostic value of 13N-ammonia myocardial perfusion positron emission tomography added value of coronary flow reserve. *J Am Coll Cardiol*. Jul 7 2009;54(2):150- 156. PMID 19573732.
22. Schindler TH, Schelbert HR, Quercioli A, et al. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. *JACC Cardiovasc Imaging*. Jun 2010;3(6):623-640. PMID 20541718.
23. Beanlands RS, Ziadi MC, Williams K. Quantification of myocardial flow reserve using positron emission imaging the journey to clinical use [editorial]. *J Am Coll Cardiol*. Jul 7 2009;54(2):157-159. PMID 19573733.
24. Gould KL, Johnson NP, Bateman TM, et al. Anatomic versus physiologic assessment of coronary artery disease. Role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making. *J Am Coll Cardiol*. Oct 29 2013;62(18):1639-1653. PMID 23954338.

25. Hsu B, Hu LH, Yang BH, et al. SPECT myocardial blood flow quantitation toward clinical use: a comparative study with ¹³N-Ammonia PET myocardial blood flow quantitation. *Eur J Nucl Med Mol Imaging*. Jan 2017;44(1):117-128. PMID 27585576.
26. Juarez-Orozco LE, Tio RA, Alexanderson E, et al. Quantitative myocardial perfusion evaluation with positron emission tomography and the risk of cardiovascular events in patients with coronary artery disease: a systematic review of prognostic studies. *Eur Heart J Cardiovasc Imaging*. Dec 27 2017. PMID 29293983.
27. Tio RA, Dabeshlim A, Siebelink HM, et al. Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. *J Nucl Med*. Feb 2009;50(2):214-219. PMID 19164219.
28. Ziadi MC, Dekemp RA, Williams KA, et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. *J Am Coll Cardiol*. Aug 9 2011;58(7):740-748. PMID 21816311.
29. Fukushima K, Javadi MS, Higuchi T, et al. Prediction of short-term cardiovascular events using quantification of global myocardial flow reserve in patients referred for clinical ⁸²Rb PET perfusion imaging. *J Nucl Med*. May 2011;52(5):726-732. PMID 21498538.
30. Slart RH, Zeebregts CJ, Hillege HL, et al. Myocardial perfusion reserve after a PET-driven revascularization procedure: a strong prognostic factor. *J Nucl Med*. Jun 2011;52(6):873-879. PMID 21571798.
31. Farhad H, Dunet V, Bachelard K, et al. Added prognostic value of myocardial blood flow quantitation in rubidium- 82 positron emission tomography imaging. *Eur Heart J Cardiovasc Imaging*. Dec 2013;14(12):1203-1210. PMID 23660750.
32. Maaniitty T, Stenstrom I, Bax JJ, et al. Prognostic value of coronary CT angiography with selective PET perfusion imaging in coronary artery disease. *JACC Cardiovasc Imaging*. Nov 2017;10(11):1361-1370. PMID 28528146.
33. Gupta A, Taqueti VR, van de Hoef TP, et al. Integrated noninvasive physiological assessment of coronary circulatory function and impact on cardiovascular mortality in patients with stable coronary artery disease. *Circulation*. Dec 12 2017;136(24):2325-2336. PMID 28864442.
34. Taqueti VR, Hachamovitch R, Murthy VL, et al. Global coronary flow reserve is associated with adverse cardiovascular events independently of luminal angiographic severity and modifies the effect of early revascularization. *Circulation*. Jan 6 2015;131(1):19-27. PMID 25400060.
35. Murthy VL, Naya M, Foster CR, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. *Circulation*. Nov 15 2011;124(20):2215-2224. PMID 22007073.
36. Murthy VL, Naya M, Foster CR, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. *Circulation*. Oct 9 2012;126(15):1858-1868. PMID 22919001.
37. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. *Heart Rhythm*. Jul 2014;11(7):1305-1323. PMID 24819193.
38. Tang R, Wang JT, Wang L, et al. Impact of patient preparation on the diagnostic performance of ¹⁸f-FDG PET in cardiac sarcoidosis: a systematic review and meta-analysis. *Clin Nucl Med*. Jul 2016;41(7):e327-339. PMID 26646995.

39. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. *J Nucl Med*. Feb 2012;53(2):241-248. PMID 22228794.
40. Sharma S. Cardiac imaging in myocardial sarcoidosis and other cardiomyopathies. *Curr Opin Pulm Med*. Sep 2009;15(5):507-512. PMID 19542892.
41. Wicks EC, Menezes LJ, Barnes A, et al. Diagnostic accuracy and prognostic value of simultaneous hybrid 18F- fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis. *Eur Heart J Cardiovasc Imaging*. Jul 1 2018;19(7):757-767. PMID 29319785.
42. Dweck MR, Abgral R, Trivieri MG, et al. Hybrid magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose to diagnose active cardiac sarcoidosis. *JACC Cardiovasc Imaging*. Jan 2018;11(1):94- 107. PMID 28624396.
43. Lapa C, Reiter T, Kircher M, et al. Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI. *Oncotarget*. Nov 22 2016;7(47):77807-77814. PMID 27780922.
44. Yokoyama R, Miyagawa M, Okayama H, et al. Quantitative analysis of myocardial (18)F-fluorodeoxyglucose uptake by PET/CT for detection of cardiac sarcoidosis. *Int J Cardiol*. Sep 15 2015;195:180-187. PMID 26043154.
45. Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). *J Am Coll Cardiol*. Oct 1 2003;42(7):1318-1333. PMID 14522503.
46. Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/SCMR/SNM 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging: A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. *J Am Coll Cardiol*. Jun 09 2009;53(23):2201-2229. PMID 19497454.
47. Earls JP, White RD, Woodard PK, et al. ACR Appropriateness Criteria(R) chronic chest pain--high probability of coronary artery disease. *J Am Coll Radiol*. Oct 2011;8(10):679-686. PMID 21962781.
48. Expert Panel on Cardiac Imaging, Akers SR, Panchal V, et al. ACR Appropriateness Criteria(R) Chronic Chest Pain-High Probability of Coronary Artery Disease. *J Am Coll Radiol*. May 2017;14(5S):S71-S80. PMID 28473096.
49. American College of Radiology (ACR). ACR Appropriateness Criteria: Chronic Chest Pain - Low to Intermediate Probability of Coronary Artery Disease. 2012; <https://acsearch.acr.org/list>. Accessed August 23, 2018.
50. American College of Radiology (ACR). ACR Appropriateness Criteria: Acute Nonspecific Chest Pain -- Low Probability of Coronary Artery Disease. 2015; <https://acsearch.acr.org/list>. Accessed August 23, 2018.

51. American College of Radiology (ACR). ACR Appropriateness Criteria: Asymptomatic Patient at Risk for Coronary Artery Disease. 2013; <https://acsearch.acr.org/list>. Accessed August 23, 2018.
52. Centers for Medicare & Medicaid Services (CMS). Coverage and Related Claims Processing Requirements for Positron Emission Tomography (PET) Scans for Breast Cancer and Revised Coverage Conditions for Myocardial Viability. Transmittal AB-02-065. 2002; <https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/ab02065.pdf>. Accessed August 23, 2018.